Zacks Investment Research on MSN1d
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
This was the stock's second consecutive day of losses.
Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...
Zacks.com on MSN1d
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key FactsBristol Myers Squibb (BMY) closed at $60.28 in the latest trading session, marking a +0.79% move from the prior day.
2don MSN
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...
7don MSN
We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...
Zacks.com on MSN3d
TSVT Up on Acquisition Agreement With BMY for $286 MillionTSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback